CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) today announced it has received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback